Mar 08 , 2022
Aggrecan, the major proteoglycan of articular cartilage, has received significant attention over the years as it is responsible for hydrating cartilage, giving it compressibility and resilience during joint loading, thereby playing a major role in the normal function of cartilage. The depletion of its glycosaminoglycan bearing aggrecan fragments has been found to be one of the earliest events in cartilage destruction. This cleavage is caused by proteases of two families: the matrix metalloprotease (MMP) family and the ADAMTS (a disintegrin-like and metalloprotease domain) family.
MD Bioproducts offers specific antibodies that recognize the termini created by these cleavage sites. These are commonly referred to as neoepitope antibodies and can be used to further understand the biochemistry of proteases and their effect on aggrecan.
Aggrecan monoclonal antibody to N-terminal Neoepitope ARG
(Mouse, Clone BC-3)
Aggrecan Antibody to N-Terminal Neoepitope ARG
(Clone BC-3), 0.1 mg/mL
Aggrecan monoclonal antibody to N-terminal Neoepitope DIPEN
(Mouse, Clone BC-4)
Aggrecan Antibody to N-Terminal Neoepitope DIPEN
(Clone BC-4), 0.1 mg/mL
This aggrecan degradation product usually remains within the tissue still complexed to hyaluronan and link protein. Its release from the cartilage usually signals that there has been extensive catabolism of aggrecan, which allows large complexes containing this metabolite to be released from tissue:
Aggrecan monoclonal antibody to C-terminal Neoepitope NITEGE
(Mouse, Clone BC-13)
Aggrecan Antibody to C-Terminal Neoepitope NITEGE
(Clone BC-13), 0.1 mg/mL
This fragment is rapidly released from tissue when MMP catabolism of aggrecan occurs and has been identified in synovial fluid samples with degenerative joint diseases:
Aggrecan monoclonal antibody to N-terminal Neoepitope FFGV
(Mouse, Clone BC-14)
Aggrecan Antibody to N-Terminal Neoepitope FFGV
(Clone BC-14), 0.1 mg/mL
Aggrecanase Activity in Cartilage
Western Blot analysis using Aggrecan Antibody to N-Terminal Neoepitope ARG
(Clone BC-3) and Aggrecan Antibody to C-Terminal Neoepitope NITEGE (Clone BC-13) on media or 4M guanidine extracts from porcine articular cartilage explant cultures exposed for 7 days to: serum-free medium alone (Con) or serum-free media containing retinoic acid (RA), interleukin-1 (IL-1) or tumor necrosis factor-α (TNFα).
Selection of recent references to our Aggrecan Antibodies to N-& C-Terminal Neoepitopes:
Kang, D., Lee, J., Jung, J., Carlson, B. A., Chang, M. J., Chang, C. B., ... & Kim, J. H. (2022). Selenophosphate synthetase 1 deficiency exacerbates osteoarthritis by dysregulating redox homeostasis. Nature Communications, 13(1), 1-14.
Clement-Lacroix, P., Little, C. B., Smith, M. M., Cottereaux, C., Merciris, D., Meurisse, S., ... & Amantini, D. (2022). Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5. Osteoarthritis and Cartilage, 30(2), 291-301.
Brebion, F., Gosmini, R., Deprez, P., Varin, M., Peixoto, C., Alvey, L., ... & Amantini, D. (2021). Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis. Journal of Medicinal Chemistry, 64(6), 2937-2952.
Researchers who brought these antibodies also use:
Monoclonal Antibody to Aggrecan IGD (Clone 6B4)
Monoclonal Antibody to Lumican (Clone Lum-1)
Monoclonal Antibody to Keratocan (Clone Ker-1)
Monoclonal Antibody to C-4-S & DS (Clone 2B6)
Monoclonal Antibody to Keratan Sulfate (Clone 5D4)
Monoclonal Antibody to Chondroitin Sulphate Neoepitope (Clone 1B5)
Monoclonal Antibody to Hyaluronic Acid Binding Region (Clone 1C6)
Monoclonal Antibody to Cartilage-Link Protein (Clone 8A4)
Monoclonal Antibody to Native Bovine Lubricin (Clone 3A4)
Monoclonal Antibody to Bovine Lubricin (Clone 6A1)